Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Athera Elects New Chairman of the Board

Published: Monday, September 23, 2013
Last Updated: Sunday, September 22, 2013
Bookmark and Share
Company moves to new premises in Stockholm.

Athera Biotechnologies AB has announced that Gunnar Olsson, former head of the global CV/GI team in AstraZeneca, has been elected new Chairman of the Board.

Earlier this year, Tomas Odergren, VP Clinical Development at Karolinska Development AB, joined the Board of Directors.

The extraordinary shareholders meeting in Athera has elected Gunnar Olsson new Chairman of the Board after Per Sjöberg, who has been leading the company for eight years.

Dr Olsson joins Athera after 24 years in AstraZeneca, where he has held several senior management positions, mainly within therapy area leadership for cardiovascular and gastrointestinal disease.

He holds an MD and PhD from Karolinska Institutet and is specialist in Cardiology and Internal Medicine. Dr Olsson is Honorary Doctor of Medicine at Gothenburg University.

Tomas Odergren, MD, PhD and specialist in Neurology, joined the Board of Directors at the Annual General Meeting in June, and he brings an excellent and well-timed expertise in clinical development. Otto Skolling remains on the Board, while Paul de Potocki and Per Sjöberg resign.

“I am very pleased to hand over to a Chairman with such strong experience from industrial drug development and business” says Per Sjöberg. “Gunnar has an extensive international network and expertise in cardiovascular drug development, and both he and Tomas will be able to make great contributions to the next development phases in Athera.”

The company has recently moved their office to new premises at Business Center on Sankt Eriksgatan 117 in Stockholm, next to Hagastaden and the new Karolinska Hospital.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
`Molecular Commando’ Identified to Tackle Hypoxia Pathway
Scientists identify 'molecular commando' that can activate hypoxic response, which helps combat a number of conditions.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Two Antibiotics Fight Bacteria Differently Than Thought
Researchers discover that two widely prescribed antibiotics may fight bacteria differently than previously thought.
Drug Target for Gastrointestinal Stromal Tumors Identified
Researchers show the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!